LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Prothena Corp PLC

Prothena Corp PLC

Suletud

Sektor Tervishoid

20.36 -1.02

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.26

Max

20.59

Põhinäitajad
By Trading Economics
Sissetulek	-72M
Müük	-266K 50K
Aktsiakasum	-1.34
Kasumimarginaal	-144,478
EBITDA	-81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+241.86 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	38M 1.2B
Eelmine avamishind	21.38
Eelmine sulgemishind	20.36

Uudiste sentiment

By Acuity

100%

340 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 21.2 Toetus ja vastupanu

Prothena Corp PLC Graafik

Seotud uudised

28. mai 2024, 22:51 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Prothena Corp PLC Prognoos

Hinnasiht

By TipRanks

241.86% tõus

12 kuu keskmine prognoos

Keskmine 69.5 USD 241.86%

Kõrge 94 USD

Madal 24 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Prothena Corp PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Prothena Corp PLC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 21.2Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

340 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

EBITDA

Ärikasum

Ettevõttest Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.